Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Assessing Aeluma, Inc: Insights Into Semiconductor Photonics

• Aeluma, Inc. (NASDAQ: ALMU) operates in the compound-semiconductor and photonics space, an area tied to optical interconnects, sensing, and data-center connectivity.

Vinay Lochav | 30 June 2026

Cerebras Systems (CBRS) Stock Moves on AI Chip Demand Risks and Outlook

• Cerebras Systems (CBRS) operates in AI semiconductors, a segment at the center of the broader artificial intelligence buildout.

Vinay Lochav | 30 June 2026

Astera Labs Gains Attention Amid AI Infrastructure Developments

• Astera Labs (NASDAQ: ALAB) designs connectivity semiconductor solutions used across AI and cloud data-center systems.

Vinay Lochav | 30 June 2026

Lightwave Logic Aims to Capture Investor Interest in Photonics Tech

• Lightwave Logic (NASDAQ: LWLG) develops electro-optic polymer materials and photonic devices aimed at faster data transmission for data centers and telecom networks.

Vinay Lochav | 30 June 2026

Corning Rallies: Is AI Data-Centre Demand Boosting Glass and Fibre Stocks?

• Corning (NYSE: GLW) operates across optical communications, display glass, specialty materials, environmental technologies, and life sciences.

Vinay Lochav | 30 June 2026

BlackSky Technology (BKSY) Stock Gains Spotlight Amid Growing Space‑Data Demand

• BlackSky Technology (NYSE: BKSY) operates in the geospatial intelligence and Earth-observation space, serving defense, government, and commercial customers.

Vinay Lochav | 30 June 2026

Tenax Therapeutics (NASDAQ: TENX) Overhauls Executive Severance Terms in Board-Approved Shake-Up

• Tenax Therapeutics (NASDAQ: TENX) board approves amendments to employment agreements for certain executives on June 26, 2026.

Vinay Lochav | 30 June 2026

Vivani Medical (NASDAQ: VANI) Overhauls Incentive Plan, Secures Australian Trial Clearance

• Vivani Medical shareholders approved an amendment to the Omnibus Incentive Plan at its most recent annual meeting.

Vinay Lochav | 30 June 2026

FDA Extends Praxis Precision Medicines (NASDAQ: PRAX) Relutrigine Review Deadline to Late December

• Praxis Precision Medicines (NASDAQ: PRAX) received a three-month extension for its relutrigine New Drug Application review, with the new FDA target action date set for late December.

Vinay Lochav | 30 June 2026

Rani Therapeutics (NASDAQ: RANI) Names Finance Veteran Nicholas Maestas as CFO

• Rani Therapeutics (NASDAQ: RANI) appoints Nicholas Maestas as Chief Financial Officer, effective June 29, 2026.

Vinay Lochav | 30 June 2026
Support

Hi! How can we help you today?

Loading…